Can Imugene’s Azer-cel Sustain Early Success Amidst Competitive CAR T Landscape?

• 100% overall response rate in CLL/SLL patients
• 80% overall response rate in marginal zone lymphoma
• Faster enrolment in CAR T-naïve cohort than CAR T-relapsed group
• Phase 1b trial expanded to include BTK inhibitor combination and mantle cell lymphoma
• Focus on prioritising indications with strongest clinical activity for fast-to-market strategy

Promising Early Clinical Signals

Imugene Limited (ASX:IMU) has unveiled encouraging early data from its Phase 1b basket trial of azer-cel, an off-the-shelf allogeneic CAR T cell therapy targeting advanced B-cell malignancies. Notably, the company reported a 100% overall response rate in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), all partial responses, despite these patients having undergone multiple prior therapies. In marginal zone lymphoma (MZL), the therapy achieved an 80% overall response rate, including several complete responses.

These results are particularly significant given the challenging nature of these diseases and the limited treatment options available for relapsed or refractory cases. Partial responses in CLL/SLL are often sufficient for regulatory approval, underscoring the potential clinical impact of azer-cel.

Expanding the Trial and Strategic Focus

The Phase 1b trial is structured as a multi-indication basket study, allowing Imugene to evaluate azer-cel across several lymphoma subtypes simultaneously. This design supports a capital-efficient development approach and the possibility of a fast-to-market strategy by prioritising indications demonstrating the strongest clinical activity.

Enrollment in the CAR T-naïve cohort is progressing more rapidly than in the earlier CAR T-relapsed diffuse large B-cell lymphoma (DLBCL) cohort, reflecting strong clinical interest and investigator support for this allogeneic approach. The trial now includes additional lymphoma types such as primary central nervous system lymphoma, Waldenström’s macroglobulinemia, and mantle cell lymphoma.

Introducing BTK Inhibitor Combination Arm

In a strategic protocol amendment, Imugene has added a combination arm evaluating azer-cel alongside Bruton Tyrosine Kinase inhibitors (BTKis), drugs that have become standard first-line treatments for CLL. This arm will focus on patients who have failed prior BTKi therapy, aiming to assess safety and preliminary efficacy in this difficult-to-treat population.

Given the global BTKi market’s substantial size, estimated at $12.1 billion in 2025, this combination could significantly broaden azer-cel’s clinical scope and commercial potential. CEO Leslie Chong highlighted the opportunity to improve outcomes for patients with limited options through this expanded program.

Looking Ahead

Imugene continues to enrol patients across multiple sites in the US and Australia, with data maturation ongoing. While early response rates are promising, durability and safety profiles remain under close observation. The company’s focus on indications with the most compelling activity suggests a nimble approach to development, potentially accelerating regulatory pathways and market entry.

As the immuno-oncology landscape evolves rapidly, Imugene’s allogeneic CAR T therapy could carve out a meaningful niche, especially if the BTKi combination proves effective. Investors and industry watchers will be keenly awaiting further data updates to gauge the therapy’s long-term potential.

Bottom Line?

Imugene’s early clinical success with azer-cel sets the stage for a pivotal phase in its development, with upcoming data likely to shape its commercial trajectory.

Questions in the middle?

• How durable are the responses observed in CLL/SLL and MZL patients over time?
• What safety signals emerge from the BTKi combination arm in heavily pretreated patients?
• Which lymphoma indications will Imugene prioritise for registration and commercialisation?